Our website uses cookies. Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and help us to understand how you use our site. Some cookies have been set. You can block and delete cookies, but parts of our site won’t work without them. By using our website, you accept our use of cookies. Find out more about cookies here.

HeartFlow Planner is now FDA Cleared! Learn more about this exciting milestone here.

close button
CT-Flow logo

Unlocking the Power of Coronary CTA

The modern way to diagnose coronary artery disease

The path to diagnosing coronary artery disease (CAD) hasn’t always been clear or reliable.1,2 Until now.

The CT-Flow pathway enables physicians to more accurately diagnose patients with suspected CAD by combining two powerful, non-invasive technologies — coronary CTA (CCTA) and the HeartFlow Analysis.1

WATCH THE VIDEO

How does the CT-Flow pathway work?

A generic CT Scanner
+
A 3D heart vessels model

The CT-Flow pathway begins with a CCTA. If the physician sees disease, the CCTA images are sent to HeartFlow, where AI algorithms, computational fluid dynamics and trained analysts create the HeartFlow Analysis. This personalized, color-coded 3-D model of a patient’s coronary arteries provides functional information about each blockage.

How is the CT-Flow pathway different?

To address the current gaps in cardiac diagnostic testing,
the CT-Flow pathway:

  • Delivers better per-vessel diagnostic performance than other non-invasive cardiac tests1
  • Provides both anatomical and lesion-specific functional information in a single patient visit
  • Identifies functional disease other non-invasive cardiac tests may overlook1,2
  • Limits invasive testing by allowing physicians to identify patients who can be treated with optimal medical therapy alone3
  • Reduces radiation exposure by up to 50% (compared to a SPECT test)4
  • Leads to better clinical decision-making and improved patient outcomes5

How do non-invasive CAD tests compare?

Choosing the appropriate diagnostic test for your patient depends on the questions you are trying to answer and the information the test will provide. Use this chart to help determine which test is best for your patient.

SPECTStress EchoCoronary CTACT-Flow
Common QuestionsA SPECT sample A Stress Echo sampleA Coronary CTA sampleA Coronary CT Flow sample
Does my patient have CAD?XXXX
Do the vessels have plaque?XX
Where are the coronary artery specific stenoses?XX
Is there possible ischemia?XXX
What are the lesion-specific functional limitations?X
Which vessels may benefit from PCI/CABG/OMT?X
Is prognostic information provided?XXXX
Diagnostic Performance *Sensitivity: 0.42
Specificity: 0.97
AUC: 0.791
Sensitivity: 0.77
Specificity: 0.75
AUC: 0.706
Sensitivity: 0.68
Specificity: 0.83
AUC: 0.831
Sensitivity: 0.90
Specificity: 0.86
AUC: 0.941
Disadvantages1-6Low sensitivity;
high rate of false positives; higher radiation exposure;
lacks anatomic data
Low sensitivity;
often requires additional testing;
lacks anatomic data
High sensitivity with low specificity leads to overutilization of invasive testing;
no functional information
Requires CCTA; Currently not as well known as other tests
Advantages1-6Accessible;
high specificity;
standard of care
Safe;
highly informative
High sensitivity identifies CAD;
provides anatomic data
More accurate than other non-invasive tests;
anatomic and functional information;
lower radiation;
single patient visit

* Diagnostic performance of SPECT, CCTA and FFRCT evaluated in a head-to-head comparison for the identification of ischaemia.

Click to Expand

How do patients benefit?

The CT-Flow pathway addresses the current gaps in traditional diagnostic testing - where patients may be misdiagnosed due to inaccurate test results.1,2

SEE PATIENT CASES

Frequently Asked Questions

How accurate is the CT-Flow pathway?

The CT-Flow pathway provides the highest diagnostic performance available from a non-invasive test to help identify functional disease.1,2 This pathway leads to targeted treatment plans and a more streamlined patient experience.

How can I best incorporate CT-Flow into my practice?

Physicians can use the CT-Flow pathway for any clinically stable symptomatic patient with CAD. The pathway requires access to a standard CT scanner and an institution that offers the HeartFlow Analysis. Find a center near you using our finder tool or contact your local HeartFlow representative.

How quickly will I get the analysis?

Within hours, physicians can receive the HeartFlow Analysis, which is available on desktop and mobile.

How will my patients benefit?

CT-Flow offers a streamlined workflow that reduces unnecessary invasive testing and radiation exposure, and provides more accurate information about their condition compared to other non-invasive cardiac tests.1,2,3,4 The highly visual, color-coded model resonates well with patients and can help increase adherence to treatment plans.

Is CT-Flow approved and covered?

Both CCTA and the HeartFlow Analysis, the two steps of the CT-Flow pathway, are commercially available. The HeartFlow Analysis is FDA cleared and reimbursed by CMS and most major commercial insurers. It’s currently available at more than 200 institutions worldwide — in the United States, United Kingdom, Europe, Canada and Japan — and has been used for more than 40,000 patients to date.

Contact Us

* Required fields
REFERENCES

1 Driessen, et al. J Am Coll Cardiol 2019; Norgaard, et al, Euro J Radiol 2015.

2 Melikian, et al. JACC: Cardiovasc Interv 2010; Jung, et al. Euro Heart J 2008. Koo, et al. J Am Coll; Cardiol 2011. Min, et al. JAMA 2012. Nørgaard, et al. J Am Coll Cardiol 2014.

3 Patel, et al. J Am Coll Cardiol 2019.

4 Stocker, et al. Euro Heart J 2018.

5 Curzen, N.P., et al., J Am Coll Cardiol 2016. Newby D.E., et al. N Engl J Med 2018.

6 Danad, et al., Euro Heart J 2017.


69473005 v1